FILING ANALYSIS · FRIDAY, NOVEMBER 13
Calidi Biotherapeutics, Inc. CLDI — 8-K: Results of Operations and Financial Condition
negative
The company's third-quarter financial results show a net loss of $3.6 million, with research and development expenses of $2.7 million and general and administrative expenses of $1.6 million, and they received $1.2 million from an at-the-market registered direct offering, which is a form of dilution. Additionally, the company executed a restructuring plan to reduce costs and extend its cash runway.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →